- Home
- HUMA vs ELDN Comparison
HUMA vs ELDN Comparison
Compare HUMA & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMA
- ELDN
- Stock Information
- Founded
- HUMA 2004
- ELDN 2004
- Country
- HUMA United States
- ELDN United States
- Employees
- HUMA 220
- ELDN N/A
- Industry
- HUMA Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- HUMA Health Care
- ELDN Health Care
- Exchange
- HUMA Nasdaq
- ELDN Nasdaq
- Market Cap
- HUMA 367.6M
- ELDN 178.4M
- IPO Year
- HUMA N/A
- ELDN N/A
- Fundamental
- Price
- HUMA $2.31
- ELDN $2.72
- Analyst Decision
- HUMA Strong Buy
- ELDN Strong Buy
- Analyst Count
- HUMA 7
- ELDN 2
- Target Price
- HUMA $13.00
- ELDN $12.50
- AVG Volume (30 Days)
- HUMA 4.1M
- ELDN 205.3K
- Earning Date
- HUMA 08-12-2025
- ELDN 08-18-2025
- Dividend Yield
- HUMA N/A
- ELDN N/A
- EPS Growth
- HUMA N/A
- ELDN N/A
- EPS
- HUMA N/A
- ELDN N/A
- Revenue
- HUMA $517,000.00
- ELDN N/A
- Revenue This Year
- HUMA N/A
- ELDN N/A
- Revenue Next Year
- HUMA $896.45
- ELDN N/A
- P/E Ratio
- HUMA N/A
- ELDN N/A
- Revenue Growth
- HUMA N/A
- ELDN N/A
- 52 Week Low
- HUMA $1.15
- ELDN $2.30
- 52 Week High
- HUMA $9.79
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- HUMA 48.99
- ELDN 35.43
- Support Level
- HUMA $2.26
- ELDN $2.76
- Resistance Level
- HUMA $2.79
- ELDN $2.90
- Average True Range (ATR)
- HUMA 0.19
- ELDN 0.16
- MACD
- HUMA -0.06
- ELDN -0.03
- Stochastic Oscillator
- HUMA 7.46
- ELDN 4.39
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.